Relevant bibliographies by topics / Assay platform

Academic literature on the topic 'Assay platform'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Assay platform.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Assay platform"

1

Chaby, Lauren E., Heather C. Lasseter, Kévin Contrepois, Reza M. Salek, Christoph W. Turck, Andrew Thompson, Timothy Vaughan, Magali Haas, and Andreas Jeromin. "Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease." Metabolites 11, no. 9 (September 8, 2021): 609. http://dx.doi.org/10.3390/metabo11090609.

Full text
Abstract:
Metabolomics methods often encounter trade-offs between quantification accuracy and coverage, with truly comprehensive coverage only attainable through a multitude of complementary assays. Due to the lack of standardization and the variety of metabolomics assays, it is difficult to integrate datasets across studies or assays. To inform metabolomics platform selection, with a focus on posttraumatic stress disorder (PTSD), we review platform use and sample sizes in psychiatric metabolomics studies and then evaluate five prominent metabolomics platforms for coverage and performance, including intra-/inter-assay precision, accuracy, and linearity. We found performance was variable between metabolite classes, but comparable across targeted and untargeted approaches. Within all platforms, precision and accuracy were highly variable across classes, ranging from 0.9–63.2% (coefficient of variation) and 0.6–99.1% for accuracy to reference plasma. Several classes had high inter-assay variance, potentially impeding dissociation of a biological signal, including glycerophospholipids, organooxygen compounds, and fatty acids. Coverage was platform-specific and ranged from 16–70% of PTSD-associated metabolites. Non-overlapping coverage is challenging; however, benefits of applying multiple metabolomics technologies must be weighed against cost, biospecimen availability, platform-specific normative levels, and challenges in merging datasets. Our findings and open-access cross-platform dataset can inform platform selection and dataset integration based on platform-specific coverage breadth/overlap and metabolite-specific performance.
APA, Harvard, Vancouver, ISO, and other styles
2

Bosse, Roger, Russell Garlick, Beverly Brown, and Luc Menard. "Development of Nonseparation Binding and Functional Assays for G Protein-Coupled Receptors for High Throughput Screening: Pharmacological Characterization of the Immobilized CCR5 Receptor on FlashPlate(r)." Journal of Biomolecular Screening 3, no. 4 (June 1998): 285–92. http://dx.doi.org/10.1177/108705719800300407.

Full text
Abstract:
G protein-coupled receptors (GPCRs) represent a very important class of drug targets. The development of microformatted nonseparation assays constitute a key step in the process of assay development for high throughput drug screening (HTS). We have developed a microformatted nonseparation assay for membrane preparations containing the CCR5 GPCR using FlashPlate® microplates (Packard Instrument Company, Meriden, CT). The pharmacodynamic (radioligand-binding) and functional (agonist-stimulated [35S]GTPγS binding) properties of this receptor observed in FlashPlate-based assays were compared with standard filtration assays. Saturation binding experiments performed using either assay platform revealed identical Kd for [125I]-MIP-1 β (0.7 nM). Comparable signal-to-noise ratios (SNR), similar affinities (Ki), and identical order of potency (RANTES ≅ MIP-1β > MIP-1α) were observed following competition binding assays in both platforms. In functional assays, the order of potency for different agonists were similar in both platforms with RANTES ≅ MIP-1β ≥ MIP-1α, which correspond to the relative affinities determined for the three ligands in competition binding experiments. Because similar pharmacologic properties were obtained in both FlashPlate microplates and standard filtration platforms, we conclude that FlashPlate microplates could provide a valuable nonseparation platform for primary and secondary HTS for this and possibly other GPCRs.
APA, Harvard, Vancouver, ISO, and other styles
3

Collet-Brose, Justine, Pierre-Jean Couble, Maureen R. Deehan, Robert J. Nelson, Walter G. Ferlin, and Sabrina Lory. "Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance." Journal of Immunology Research 2016 (2016): 1–15. http://dx.doi.org/10.1155/2016/5069678.

Full text
Abstract:
The aim of this study was, at the assay development stage and thus with an appropriate degree of rigor, to select the most appropriate technology platform and sample pretreatment procedure for a clinical ADA assay. Thus, ELISA, MSD, Gyrolab, and AlphaLISA immunoassay platforms were evaluated in association with target depletion and acid dissociation sample pretreatment steps. An acid dissociation step successfully improved the drug tolerance for all 4 technology platforms and the required drug tolerance was achieved with the Gyrolab and MSD platforms. The target tolerance was shown to be better for the ELISA format, where an acid dissociation treatment step alone was sufficient to achieve the desired target tolerance. However, inclusion of a target depletion step in conjunction with the acid treatment raised the target tolerance to the desired level for all of the technologies. A higher sensitivity was observed for the MSD and Gyrolab assays and the ELISA, MSD, and Gyrolab all displayed acceptable interdonor variability. This study highlights the usefulness of evaluating the performance of different assay platforms at an early stage in the assay development process to aid in the selection of the best fit-for-purpose technology platform and sample pretreatment steps.
APA, Harvard, Vancouver, ISO, and other styles
4

Dunn, D., M. Orlowski, P. McCoy, F. Gastgeb, K. Appell, L. Ozgur, M. Webb, and J. Burbaum. "Ultra-High Throughput Screen of Two-Million-Member Combinatorial Compound Collection in a Miniaturized, 1536-Well Assay Format." Journal of Biomolecular Screening 5, no. 3 (June 2000): 177–87. http://dx.doi.org/10.1177/108705710000500310.

Full text
Abstract:
Results of a complete survey of the more than 2-million-member Pharmacopeia compound collection in a 1536-well microvolume screening assay format are reported. A complete technology platform, enabling the performance of ultra-high throughput screening in a miniaturized 1536-well assay format, has been assembled and utilized. The platform consists of tools for performing microvolume assays, including assay plates, liquid handlers, optical imagers, and data management software. A fluorogenic screening assay for inhibition of a protease enzyme target was designed and developed using this platform. The assay was used to perform a survey screen of the Pharmacopeia compound collection for active inhibitors of the target enzyme. The results from the survey demonstrate the successful implementation of the ultra-high throughout platform for routine screening purposes. Performance of the assay in the miniaturized format is equivalent to that of a standard 96-well assay, showing the same dependence on kinetic parameters and ability to measure enzyme inhibition. The survey screen identified an active class of compounds within the Pharmacopeia compound collection. These results were confirmed using a standard 96-well assay.
APA, Harvard, Vancouver, ISO, and other styles
5

Thompson, Iain, John McGiven, Jason Sawyer, Rachel Thirlwall, Nicola Commander, and Judy Stack. "Competitive Electrochemiluminescence Wash and No-Wash Immunoassays for Detection of Serum Antibodies to Smooth Brucella Strains." Clinical and Vaccine Immunology 16, no. 5 (March 4, 2009): 765–71. http://dx.doi.org/10.1128/cvi.00006-09.

Full text
Abstract:
ABSTRACT Brucellosis is a bacterial zoonotic disease of major global importance. Natural hosts for Brucella species include animals of economic significance, such as cattle and small ruminants. Controlling brucellosis in natural hosts by high-throughput serological testing followed by the slaughter of seropositive animals helps to prevent disease transmission. This study aimed to convert an existing competitive enzyme-linked immunosorbent assay (cELISA), used for the serodiagnosis of brucellosis in ruminants, to two electrochemiluminescence (ECL) immunoassays on the Meso Scale Discovery (MSD) platform. The first assay employed a conventional plate washing step as part of the protocol. The second was a no-wash assay, made possible by the proximity-based nature of ECL signal generation by the MSD platform. Both ECL wash and no-wash assays closely matched the parent cELISA for diagnostic sensitivity and specificity. The results also demonstrated that both ECL assays met World Organization for Animal Health (OIE) standards, as defined by results for the OIE standard serum (OIEELISASPSS). This report is the first to describe an ECL assay incorporating lipopolysaccharide, an ECL assay for serodiagnosis of a bacterial infectious disease, a separation-free (no-wash) ECL assay for the detection of serum antibodies, and the use of the MSD platform for serodiagnosis. The simple conversion of the cELISA to the MSD platform suggests that many other serodiagnostic tests could readily be converted. Furthermore, the alignment of these results with the multiplex capability of the MSD platform offers the potential of no-wash multiplex assays to screen for several diseases.
APA, Harvard, Vancouver, ISO, and other styles
6

Zhao, Yanan, Yoji Nagasaki, Milena Kordalewska, Ellen G. Press, Ryan K. Shields, M. Hong Nguyen, Cornelius J. Clancy, and David S. Perlin. "Rapid Detection ofFKS-Associated Echinocandin Resistance in Candida glabrata." Antimicrobial Agents and Chemotherapy 60, no. 11 (August 22, 2016): 6573–77. http://dx.doi.org/10.1128/aac.01574-16.

Full text
Abstract:
ABSTRACTA novel and highly accurate diagnostic assay platform was established for rapid identification ofFKSmutations associated with echinocandin resistance inCandida glabrata. The assay platform uses allele-specific molecular beacon and DNA melt analysis following asymmetric PCR. A dual assay forFKS1andFKS2was developed to identify within 3 h the most common and clinically relevant resistance-associated mutations, including 8FKS1HS1 (wild type [WT], S629P, F625S, D632Y, D632E [T1896G], D632E [T1896A], I634V, and F625F) and 7FKS2HS1 (WT, F659del, F659S, F659V, F659L, S663P, and S663F) genotypes. A blinded panel of 188C. glabrataclinical isolates was tested by both assays. The molecular diagnostic results from the dual assay were 100% concordant with data obtained from DNA sequencing. This platform has the potential to overcome the deficiencies of existingin vitrosusceptibility-based assays to identify echinocandin-resistantC. glabrataand holds promise as a surrogate diagnostic method to better direct echinocandin therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Ward, Matthew D., Kristin E. Mullins, Elizabeth Pickett, VeRonika Merrill, Mark Ruiz, Heather Rebuck, Show-Hong Duh, and Robert H. Christenson. "Performance of 4 Automated SARS-CoV-2 Serology Assay Platforms in a Large Cohort Including Susceptible COVID-19–Negative and COVID-19–Positive Patients." Journal of Applied Laboratory Medicine 6, no. 4 (March 10, 2021): 942–52. http://dx.doi.org/10.1093/jalm/jfab014.

Full text
Abstract:
Abstract Background Anti–SARS-CoV-2 serological responses may have a vital role in controlling the spread of the disease. However, the comparative performance of automated serological assays has not been determined in susceptible patients with significant comorbidities. Methods In this study, we used large numbers of samples from patients who were negative (n = 2030) or positive (n = 112) for COVID-19 to compare the performance of 4 serological assay platforms: Siemens Healthineers Atellica IM Analyzer, Siemens Healthineers Dimension EXL Systems, Abbott ARCHITECT, and Roche cobas. Results All 4 serology assay platforms exhibited comparable negative percentage of agreement with negative COVID-19 status ranging from 99.2% to 99.7% and positive percentage of agreement from 84.8% to 87.5% with positive real-time reverse transcriptase PCR results. Of the 2142 total samples, only 38 samples (1.8%) yielded discordant results on one or more platforms. However, only 1.1% (23/2030) of results from the COVID-19–negative cohort were discordant. whereas discordance was 10-fold higher for the COVID-19–positive cohort, at 11.3% (15/112). Of the total 38 discordant results, 34 were discordant on only one platform. Conclusions Serology assay performance was comparable across the 4 platforms assessed in a large population of patients who were COVID-19 negative with relevant comorbidities. The pattern of discordance shows that samples were discordant on a single assay platform, and the discordance rate was 10-fold higher in the population that was COVID-19 positive.
APA, Harvard, Vancouver, ISO, and other styles
8

Suhandynata, Raymond T., Melissa A. Hoffman, Michael J. Kelner, Ronald W. McLawhon, Sharon L. Reed, and Robert L. Fitzgerald. "Multi-Platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19." Journal of Applied Laboratory Medicine 5, no. 6 (August 7, 2020): 1324–36. http://dx.doi.org/10.1093/jalm/jfaa139.

Full text
Abstract:
Abstract Background COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel beta-coronavirus that is responsible for the 2019 coronavirus pandemic. Acute infections should be diagnosed by polymerase chain reaction (PCR) based tests, but serology tests can demonstrate previous exposure to the virus. Methods We compared the performance of the Diazyme, Roche, and Abbott SARS-CoV-2 serology assays using 179 negative participants to determine negative percentage agreement (NPA) and in 60 SARS-CoV-2 PCR-confirmed positive patients to determine positive percentage agreement (PPA) at 3 different time frames following a positive SARS-CoV-2 PCR result. Results At ≥15 days, the PPA (95% CI) was 100 (86.3–100)% for the Diazyme IgM/IgG panel, 96.0 (79.7–99.9)% for the Roche total Ig assay, and 100 (86.3–100)% for the Abbott IgG assay. The NPA (95% CI) was 98.3 (95.2–99.7)% for the Diazyme IgM/IgG panel, 99.4 (96.9–100)% for the Roche total Ig assay, and 98.9 (96.0–99.9)% for the Abbott IgG assay. When the Roche total Ig assay was combined with either the Diazyme IgM/IgG panel or the Abbott IgG assay, the positive predictive value was 100% while the negative predictive value remained greater than 99%. Conclusions Our data demonstrates that the Diazyme, Roche, and Abbott SARS-CoV-2 serology assays have similar clinical performances. We demonstrated a low false-positive rate across all 3 platforms and observed that false positives observed on the Roche platform are unique compared to those observed on the Diazyme or Abbott assays. Using multiple platforms in tandem increases the PPVs, which is important when screening populations with low disease prevalence.
APA, Harvard, Vancouver, ISO, and other styles
9

Hemmila, Ilkka. "LANCE™: Homogeneous Assay Platform for HTS." Journal of Biomolecular Screening 4, no. 6 (December 1999): 303–7. http://dx.doi.org/10.1177/108705719900400604.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Fang-yuan, Zheng Wang, Peng Li, Hong-Zhen Lian, and Hong-Yuan Chen. "Aptamer-based thrombin assay on microfluidic platform." ELECTROPHORESIS 34, no. 24 (November 18, 2013): 3260–66. http://dx.doi.org/10.1002/elps.201300338.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Assay platform"

1

Harrison, Olivia Jane. "Integrated platform to assay melanoblast development in vitro." Thesis, University of Edinburgh, 2018. http://hdl.handle.net/1842/31164.

Full text
Abstract:
Melanoblasts are the embryonic precursors of melanocytes, the pigment producing cells of the skin and hair. Melanoblasts are of key interest to developmental biologists for numerous reasons, including their ability to migrate throughout the body from a single origin in the neural crest (NC). Current methods for the study of the melanocyte lineage are limited by the heavy reliance on animal models. To challenge this, a platform of in vitro tools were designed to replace and complement current studies. A major obstacle is the transition from 2D cultures, which provide only limited behavioural information, to 3D models which are able to recapitulate the environmental conditions. 3D cultures are regularly created using tissue samples and synthetic matrices for attachment, but building a model from cell lines only has not been achieved. A co-culture model using immortalised keratinocyte (COCA) and melanoblast cell lines proved unsuitable for observing developmental processes, due to lack of movement at high cell densities, but may be practical in pigmentation research. Other methods were explored to examine melanoblast behaviour, including the use of cell derived matrices (CDMs) integrated with melanoblast cell lines, and aggregates formed by hanging drop (HD) culture. CDMs were successfully generated from the COCA line, as well as NIH3T3 fibroblasts which has been shown previously. These structures are denuded of cells to leave the deposited extracellular matrix (ECM) components intact, representative of the dermal (fibroblast) and epidermal (keratinocyte) layers of the skin. HDs were prepared from cultured melanoblast cell lines, and form tight aggregates which disseminate when plated, in a manner similar to the dissemination of cells from the NC in explant cultures. The receptor tyrosine kinase KIT and its ligand (KITL), are vital for melanoblast development. Previous study of this signalling complex has often focussed on the haematopoietic lineage and spermatogenesis, where they perform essential roles. KITL is expressed in a membrane localised form found on the surface of keratinocytes thought to promote melanoblast/melanocyte survival, and a soluble isoform found sequestered in the ECM which promotes cell migration. Cell lines expressing fluorescently tagged KIT and KITL were created to visualise their interactions using live-cell confocal imaging. Firstly, cell lines were generated to perform co-culture experiments with KIT and KITL, and we showed that these constructs are able to interact by uptake of KITL into KIT cells. Secondly, tandem fluorescent protein timers of KIT and KITL were generated which were used to observe protein kinetics. We showed that these protein timers can be manipulated using cycloheximide to block protein production, or by increasing ligand availability. These protein timers reveal that soluble KITL (sKITL) has a faster turnover than membrane bound KITL (mKITL), and that in all three proteins, there is distinct change in spatial localisation as the proteins age. Using a novel melanoblast reporter mouse, Pmel-CMN, primary mouse melanoblasts between E12.5 and E14.5 were isolated for RNA sequencing. This time period is the earliest reported for melanoblast isolation for use in gene expression analysis. We show that within this time course, there are significant changes in the RNA expression profiles, including decreasing expression of other NC cell markers, and huge increasing expression of pigmentation genes. To assess the biological relevance of using in vitro assays, cells of the immortalised melanoblast cell line, melb-a, were cultured under different conditions and examined via RNA sequencing. Results reveal differences in several areas between primary cells and those in culture, including loss of melanocyte specificity. The different tools described in this thesis provide a platform on which to study various aspects of cell behaviour, including migration, morphology and cell adhesion at both the individual cell and population levels.
APA, Harvard, Vancouver, ISO, and other styles
2

Sun, Han. "Novel microfluidic platform for bioassays." HKBU Institutional Repository, 2019. https://repository.hkbu.edu.hk/etd_oa/699.

Full text
Abstract:
Microfluidics have been created to acquire, operate, and process complex fluids in extremely tiny volumes with high efficiency and high speed, and without the requirement for an experienced operator. In addition, microfluidic systems also enable miniaturization and incorporation of different complex functions, which can help bring intricate diagnostic tools out of the laboratories. Ideally, these systems should be inexpensive, precise, reliable, robust, and well-suited to the medical diagnostic systems. Most of the microfluidic devices reported previously were based on devices made of polydimethylsiloxane (PDMS). PDMS is a material that dissolves in many common organic solvents. Meanwhile, it is also prone to absorb small molecules like the proteins, which is detrimental to a stable and reliable result. Current work focuses on bioassays that are badly needed in our life and these bioassays are addressed based on microfluidic platform with different materials. The translation of microfluidic technology into large scale implementations highly relies on new materials that address the limitations of PDMS. Firstly, we fabricated two different microfluidic platforms for rapid antimicrobial susceptibility testing (AST). One was made of hydrogel, and the bacterial cells were cultured on the top of the device; the other was of polypropylene (PP), and bacterial cells were cultured inside the microchannels. Meanwhile, we developed a novel "barcode" sensor, a microscope-free method for cell accumulation and cell counting, as the downstream of the PP-based chips. As a result, AST can be accomplished simply through an application on a mobile phone rather than using an expensive and sophisticated microscope. Secondly, we presented a self-contained paper-based system for lead(II) ion detection based on G-quadruplex-based luminescence switch-on assay, comprising a novel type of paper-based chip and a matching portable device. Different from the reported paper-based devices, the paper substrate we chose was art paper, which is used for printing magazines. This type of paper could prevent the absorption of liquid into the paper matrix and hold the liquid in place for a period of time; and it could also be used for temporary liquid containing like a plastic substrate (such as polypropylene (PP) and polystyrene (PS)), but the surface of the paper is inherently hydrophilic. In such a design, liquid drops are suspended on the surface of the device in designed reservoirs, rather than absorbed into the paper; when the chip is tilted, the liquid drops will move to other reservoirs according to the guidance of channels defined on the surface. To differentiate it from reported μPAD devices that are fabricated with water-permeable paper, we name this new type of paper-based devices suspending-droplet mode paper-based microfluidic devices (SD-μPAD). Different from the conventional μPADs that use capillary force to drive liquid, our SD-μPADs uses wetting and gravity as driving force. To fabricate the superhydrophobic pattern on the paper device, we developed a new microcontact printing-based method to produce inexpensive and precisely patterned superhydrophobic coating on paper. The coating material is poly(dimethylsiloxane) (PDMS), a hydrophobic and transparent silicone that has long been used for fabricating microfluidic devices. Importantly, the negative-relief stamp we used is made of Teflon, a non-stick polymer, so that the PDMS-coated paper could be peeled from the stamp flawlessly. After such fabrication process, the stamped area of the paper is coated with a textured PDMS layer that is decorated with arrays of micropillars, which could provide superhydrophobic effect and most effectively hold the droplets in place; the remaining area of the paper is still hydrophilic. As a demonstration of this new design, we developed a method using the reaction characteristics of iridium(III) complex for rapid, onsite detection of lead(II) ions in liquid samples. As the reagents have already been loaded onto the paper device during fabrication, the only reagent the users need to add is water. Because of the large Stokes shift of the iridium(III) complex probe, inexpensive optical filters can be employed, and we were able to make an inexpensive, battery-powered compact device for routine portable detection using a smartphone as a detector, allowing the rapid analysis and interpretation of results on site as well as the automatic dissemination of data to professional institutes, including tests even in poor rural areas in developing countries. Thirdly, we upgraded our suspending-droplet mode paper-based microfluidic device (SD-μPAD), which is used for the detection of lead(II) ions in liquid solution. The reason is that our paper-based SD chips are not suitable for long reaction process (> 20 min) detection of biomolecules due to the potential permeation and contaminating problems of art papers. Hence, we chose polypropylene (PP), a hydrophobic, cheap, and thermal stable material (< 110°C), as the material for the fabrication of the SD microfluidic chip. We established a convenient, low-cost, portable and reliable platform for monitoring VEGF165 accurately, which can be applied for point-of-care (POC) testing. In this project, we also employed the label-free oligonucleotide-based luminescence switch-on assay on the microfluidic platform, which possesses the advantages of high sensitivity and high selectivity. Based on the detection of VEGF165 in a three-step reaction process, we adopted a new design for the droplet transfer throughout the channels. This design could migrate the droplet through the chambers via controlling the orientation of the chip, which systematically combined the superhydrophobic force of the coating, the gravity of the droplet and the surface tension between PP and droplet. Therefore, traditional micro pump could be avoided and the total cost for the device could be substantially reduced. In addition, we developed an automatic, matched and portable device for the detection of VEGF165, which assembled by a rotatable chip holder, a UV lamp, a filter, and a camera. Finally, we developed a new whole Teflon membrane-based chip for the aptamer screening. Our article "Whole-Teflon microfluidic chips" introduced the fabrication of a microfluidic device entirely using Teflon materials, one group of the most inert materials in the world. It was a successful and representative introduction of new materials into the fabrication of microfluidic devices, which show dramatically greater anti-fouling performance. However, even such device was inadequate for current purpose, as it is rigid and lacks convenient valve control functions for particle suspensions used in systematic evolution of ligands by exponential enrichment (SELEX). For this project, we propose a SMART screening strategy based on a highly integrated microfluidic chip. This new type of whole-Teflon devices, which are made of flexible Teflon membranes, offering convenient valving control for the whole SELEX process to be performed on chip and fulfilling the anti-fouling requirement in the meantime. The SELEX cycles including positive and negative selections could be automatically performed inside tiny-size microchambers on a microchip, and the enrichment is real-time monitored. The selection cycles would be ended after the resulted signal of the aptamers with high specificity reached a plateau, or no target aptamer is captured after a number of cycles of enrichment. Owning to the antifouling property of the chip materials, the loss of the sample is tremendously reduced. The SMART platform therefore is not only free of complicated manual operations, but also high-yield and well reproducible over conventional methods
APA, Harvard, Vancouver, ISO, and other styles
3

Spetsare, Ebba. "Optimization of a pharmacokinetic assay in a bridging assay format using the Gyrolab immunoassay platform." Thesis, Uppsala universitet, Biokemi, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396493.

Full text
Abstract:
Anti-TNF alpha antibodies were among the first approved antibody drugs and now belongs to the best-selling drugs. Today, several companies are developing biosimilars to those drugs which will increase the access of medications and potentially reduce health care costs. There is a great demand for pharmacokinetic assays for anti-TNF-alpha drugs and the bridging assay format is a potential tool, mostly due to its high serum tolerance. This project at Gyros Protein Technologies AB aimed to investigate the properties of the solid phase on the Gyrolab and to utilize this to optimize the bridging assay to be used as a pharmacokinetic assay for a human antibody in the presence of serum. The solid phase was optimized by incorporating three reagents with increasing molecular weight and examining the column profiles generated. Furthermore, the capture reagent was titrated with b-BSA to avoid cross-binding of both arms of the antibody to the capture reagent. Since the background was relatively high, further optimization was done to reduce background and increase the signal to noise ratio. The performance of the optimized bridging assay was compared to alternative PK assay formats. The estimated sensitivity of the bridging assay was 5 ng/ml compared to 250 ng/ml for the indirect antibody assay and 2.5 ng/ml for the bridging assay using an anti-idiotypic antibody as detect. The optimized bridging assay performed well without dilution in buffer and was therefore used for affinity determination of Humira in neat serum. Variable concentrations of TNF-alpha were added to a fix concentration of Humira to compete with the interaction. Calculated KD-values were similar regardless of whether the measurements were performed in neat serum or after dilution in Rexxip buffer.
APA, Harvard, Vancouver, ISO, and other styles
4

Bucco, Olgatina, and olgatina@gmail com. "Preparing, measuring and capturing G-protein coupled receptor (GPCR) signalling complexes for future development of cell-free assay technologies." Flinders University. medicine, 2006. http://catalogue.flinders.edu.au./local/adt/public/adt-SFU20060703.114912.

Full text
Abstract:
G-protein coupled receptors (GPCRs) are integral membrane proteins which represent primary cellular targets for intracellular signalling. Many of these receptors are altered in disease states and hence are the target for over 50% of marketed drugs. Despite their physiological importance, high-throughput, cell-free assays which measure functional or signalling activity are only recently being investigated. The current approach by the pharmaceutical industry to initially screen compounds for functionality is to use heterologous cell-based assay formats. The aim of this work was to reconstitute a cell-free GPCR signalling system on an appropriate platform (surface) as a prototype for future rapid drug screening and other applications. The proof-of-concept approach involved using the �2A-adrenergic receptor (�2A-AR) containing cell membrane preparations as the model GPCR, reconstituted with a set of heterotrimeric G-proteins; G�i1 and �1�2 (the signal transducing complex being termed a �transductosome�). However, other receptors and G-proteins were also investigated. Receptors were initially obtained from natural (tissue) sources, however in the later stages they were expressed in a heterologous system (insect or mammalian expression system). G-proteins were expressed in Spodoptera frugiperida (Sf9) insect cells using the baculovirus expression system. Receptor expression was verified by radioligand binding assays and endogenous G-proteins were removed from membrane preparations using the chaotropic agent urea to allow for reconstitution with purified G-proteins. Signal transduction through the transductosome was measured using the [35S]GTP�S binding assay. Receptor activated [35S]GTP�S binding was used to determine functional reconstitution and to validate that the system was working in the normal physiological manner both on and off a surface (with surface attachment being via histidine attachment on the G�i1 (6xHIS) subunit). Using the captured (surface-attached) transductosomes, the IC50 values for Rauwolscine, Yohimbine (potent �2-AR antagonists), Prazosin (potent �1- AR antagonist) and Propranolol (�-AR antagonist) displayed the appropriate rank order for this class of receptor. This cell-free, surface-attached signalling complex prototype may have use in the future development of drug screening and discovery assay technologies as well as other applications as an alternative to cell-based assays which are not readily amendable to miniaturisation, long term storage and therefore stable robust microarray formats.
APA, Harvard, Vancouver, ISO, and other styles
5

Tothill, Alexander M. "Developing a proof of principle 3D-printed lab-on-a-disc assay platform." Thesis, Cranfield University, 2017. http://dspace.lib.cranfield.ac.uk/handle/1826/13496.

Full text
Abstract:
A 3D-printed microfluidic lab-on-a-disc (LOAD) device was designed and manufactured using a low cost ( ̃£1600) consumer grade fused deposition modelling (FDM) Ultimaker 2+ 3D printer with imbedded microfluidic channels 1 mm wide, 400 μm depth and with a volumetric capacity of approximate 23 μl. FDM printers are not typically used, or are capable, of producing the fine detailed structures required for microfluidic fabrication; in addition 3D-printed objects can suffer from poor optical transparency. However, in this work, imbedded microfluidic channels were produced and the optical transparency of the device was improved though manufacture optimisation to such a point that optical colourimetric assays can be performed in a microfluidic cuvette device with sample path length of 500 μm and volumetric capacity of 190 μl. When acetone vapour treatment was used, it was possible to improve transparency of plastic samples by up to a further 30%. The LOAD device is capable of being spun using an unmodified optical disc drive (ODD), demonstrating the centrifugation based separation of plasma from whole blood in a low-cost FDM 3D-printed microfluidic LOAD device. A cholesterol assay and glucose assay was developed and optimised using cholesterol oxidase (ChOx) or glucose oxidase (GlOx) respectively and horseradish peroxidase (HRP) for the oxidative coupling of chromotropic acid (CTA) and 4-aminoantipyrine (AAP). This produced a blue quinoneimine dye with a broad absorbance peaking at 590 nm for the quantification of cholesterol/glucose in solution. The colourimetric enzymatic cascade assays were developed for use within low-cost FDM 3D-printed microfluidic devices to demonstrate the capabilities and functionality of the devices. For comparison, the assay was run in standard 96 well plates with a commercial plate reader. The results demonstrated that the quantification of 0-10 mM glucose solution using a 3D-printed microfluidic optical device had a performance comparable to a plate reader assay; glucose assay in whole blood samples R2 = 0.96.
APA, Harvard, Vancouver, ISO, and other styles
6

Ismail, Awale Nasteho. "Validation of a tetraplex assay for detection of antibodies in poultry serum using Luminex 200 platform." Thesis, Uppsala universitet, Institutionen för medicinsk biokemi och mikrobiologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-181920.

Full text
Abstract:
Background: As a part of a national health control program, Statens VeterinärmedicinskaAnstalt performs diagnostics to screen flocks for certain pathogens causing high mortality,morbidity and/or serious economical losses. There are several viruses in the programincluding IBDV (infectious bursal disease virus), IBV (infectious bronchitis virus) and NDV(Newcastle disease virus). Method: 96 serum samples were collected from different poultryflocks in Sweden and analyzed by ELISA, which are currently used in the health controlprogram as well as by a commercial prototype of a multiplex immunoassay manufactured byLuminex Corp., which is currently under evaluation at the United States Department ofAgriculture USDA. This 4-plex assay detects antibodies for the three above-mentionedviruses as well as antibodies of avian reovirus. In the context of this study the ELISAs run inroutine diagnostics as well as a REO ELISA were used as the standard for comparison.Result: The antibody concentration in serum from vaccinated chickens was high while theantibody concentration level in serum from not vaccinated chickens was low. There was agood correlation between the multiplex assay and ELISA. Conclusion: The results obtainedin this study indicate that the Luminex multiplex assay tested has the potential to be usedroutinely for screening flocks.
APA, Harvard, Vancouver, ISO, and other styles
7

Cheow, Lih Feng. "Development of a concentration-enhanced mobility shift assay platform for aptamer-based biomarker detection and kinase profiling." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/71513.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science, 2012.
Cataloged from PDF version of thesis.
Includes bibliographical references.
New methods to quantify rare biomarkers from patient samples are critical for developing point-of- care diagnostic platforms. To be compatible with resource limited settings, these assays have to provide fast and accurate results without sacrificing ease of use. Biosensing in homogeneous fashion is the preferred format which satisfies these criteria, but the lack of amplification method is a bottleneck that limits their use for sensitive applications. To address this issue, this thesis explores physical signal amplification means to increase the sensitivities of homogeneous assays. We identified several key applications where the use of these technologies could make a positive impact in improving medical diagnostics systems and advancing biological research. We first outline the use of electrokinetic concentration to realize a continuous signal amplification scheme that increases the sensitivity of homogeneous mobility shift assays. By simultaneously concentrating and separating reacted and unreacted species (with different mobilities) in this device, we can perform sensitive, quantitative and ratiometric measurement of target biomarkers. Using this platform, we improved the sensitivity of aptamer affinity probe capillary electrophoresis to achieve pM detection limit of IgE and HIV-RT in simple buffer and serum sample. This work is timely and impactful as it directly addresses the sensitivity shortcomings of using aptamers as low cost and robust substitutes for antibodies in point-of-care applications. Next, we presented a herringbone nanofilter array device which can perform continuous sizes-elective concentration of biomolecules based on their direct interaction with nanostructures with comparable critical dimensions. We demonstrated the use of this platform to perform a novel homogeneous immunoassay for detecting a cardiac biomarker, C-reactive protein, at clinically relevant concentrations. Finally, we demonstrated that the concentration-enhanced mobility shift assay platform is a powerful tool for probing biological activities such as cellular kinase activities. We have developed technology to isolate, grow and lyse single cells, and used our platform to measure kinase activities from single cells. Through rational design of peptide substrates and spacers, this platform has the ability to simultaneously concentrate and separate multiple analytes. This enables users to obtain simultaneous measurements of multiple cellular kinase activities that could reveal important information about their functional relationships.
by Lih Feng Cheow.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
8

Bracht-Loman, Jillian Wilhelmina Paulina. "Validation of liquid biopsy-based analysis on the NanoString nCounter platform." Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/672549.

Full text
Abstract:
L'avaluació dels marcadors moleculars en teixit tumoral per predir el pronòstic del càncer i la resposta al tractament, també coneguda com a tractament personalitzat, ha transformat la pràctica clínica per a molts tipus de càncer. Es va descobrir que aquesta teràpia dirigida per genotipar, millora la supervivència del pacient i per tant s'han introduït diverses plataformes tècniques en els laboratoris clínics. No obstant això, no tots els tumors es poden biopsiar i, sovint, les quantitats de teixit són insuficients per a la caracterització del tumor. L'ARN, l'ADN i les proteïnes lliures circulants de biòpsies líquides, es poden extreure dels fluids corporals i poden reemplaçar o complementar les biòpsies de teixit. Les biòpsies líquides tenen diversos avantatges: la possibilitat de realització d’ estudis de serie o mínimament invasiva i permet analitzar l'heterogeneïtat tumoral. Malauradament, encara hi ha una gran bretxa entre la recerca bàsica i la implementació clínica de biòpsies líquides, principalment a causa de la manca de metodologies estandarditzades. A més, les plataformes tècniques que s'utilitzen actualment, no sempre són adequades per analitzar la baixa quantitat i qualitat de material del tumor derivat d'una biòpsia líquida. En conseqüència, la validació i implementació dels assajos de biomarcadors en biòpsies líquides en els laboratoris clínics, requereixen una plataforma tècnica estandarditzada que sigui sensible, ràpida, fàcil d'utilitzar, relativamente econòmica, flexible i amb poca quantitat de mostra. La plataforma nCounter es pot utilitzar per analitzar tota classe de molècules, inclosos ARN, ADN i proteïnes. La hibridació de codis de barres codificats per colors pels objectius d'interès permet una lectura directa dels nivells d'expressió de gens i proteïnes o la detecció de mutacions. El desenvolupament d'assaigs de biomarcadors en teixits, usant el nCounter, va conduir a l'aprovació per la FDA de l'assaig Prosigna™ per a ús clínic en la tipificació del càncer de mama. Els esforços anteriors també han destacat el potencial d'aquesta plataforma per analitzar molècules derivades i amplificades de biòpsies líquides, encara que es necessiten estudis de validació en l'entorn clínic. En aquesta tesi validem l'ús de la plataforma NanoString nCounter per analitzar material de biòpsies líquides i desenvolupar assajos de biomarcadors clínicament rellevants.
La evaluación de los marcadores moleculares en tejido tumoral para el pronóstico del cáncer y la predicción de respuesta al tratamiento (lo que habitualmente se conoce como tratamiento personalizado) ha transformado la práctica clínica a la hora de tratar muchos tipos de cáncer. Son numerosos los trabajos que desde hace tiempo respaldan el efecto que esta terapia dirigida por genotipo tiene sobre los pacientes oncológicos mejorando la supervivencia del paciente; consecuentemente, un amplio rango de plataformas técnicas han sido implementadas en los laboratorios clínicos en los últimos años. Sin embargo, no todos los tumores se pueden biopsiar y, a menudo, las cantidades de tejido son insuficientes para la caracterización del tumor. Las biopsias líquidas, como el ARN, el ADN o las proteínas circulantes tanto libres como encapsuladas en una membrana, pueden extraerse de los fluidos corporales reemplazando o complementando de este modo las tradicionales biopsias de tejido. Las biopsias líquidas tienen varias ventajas: ofrecen la posibilidad de realizar estudios seriados, son mínimamente invasivas y permiten analizar la heterogeneidad tumoral. Desafortunadamente, todavía existe una gran brecha entre la investigación básica y la implementación clínica de las biopsias líquidas, principalmente debido a la falta de metodologías estandarizadas. Además, las plataformas técnicas que se utilizan actualmente no siempre son adecuadas para analizar la baja cantidad y calidad de material del tumor procedente de una biopsia líquida. En consecuencia, la validación e implementación de los ensayos de biomarcadores en biopsias líquidas en los laboratorios clínicos requieren una plataforma técnica estandarizada que sea sensible, rápida, fácil de usar, viable económicamente, flexible y que requiera un aporte inicial de ácidos nucleicos bajo, debido a la baja concentración que normalmente se obtiene en las biopsias líquidas. La plataforma nCounter se puede utilizar para analizar todo tipo de moléculas, incluyendo ARN, ADN y proteínas. La hibridación de diferentes códigos formados por moléculas de colores siguiendo patrones específicos con secuencias de interés permite una lectura directa de los niveles de expresión de genes y proteínas o la detección de mutaciones. El desarrollo de ensayos de biomarcadores en tejidos usando nCounter condujo a la aprobación por la administración de fármacos y alimentos de los Estados Unidos (FDA) del ensayo Prosigna ™ para su uso clínico en la tipificación del cáncer de mama. Numerosos estudios han destacado el potencial de esta plataforma para analizar moléculas derivadas y amplificadas de biopsias líquidas, aunque estudios de validación en el entorno clínico aun son necesarios. El objeto de esta tesis es la validación del uso de la plataforma NanoString nCounter para analizar material de biopsias líquidas y desarrollar ensayos de biomarcadores clínicamente relevantes.
The assessment of predictive- and prognostic molecular markers in tumor tissue, also known as personalised treatment, has transformed clinical practice for many cancer types. This genotype-directed therapy was found to improve patient survival, and several technical platforms have been introduced in clinical laboratories since then. However, not all tumors can be biopsied and tissue quantities are often insufficient for tumor characterisation. Liquid biopsies, such as membrane-encapsulated- or circulating free RNA, DNA and proteins, can be derived from body fluids and can replace or complement tissue biopsies. They have several advantages, such as repeated sampling, a minimally invasive character and heterogeneous profiling. Unfortunately, there is still a big gap between basic research and clinical implementation of liquid biopsies, mainly due to the lack of standardised methodologies. In addition, currently used technical platforms are not always suitable to analyze the low quantity and quality of tumor-derived material that can be found in a liquid biopsy. In consequence, large-scale validation and clinical implementation of liquid biopsy-based biomarker assays requires a sensitive, quick, easy-to-use, relatively cheap, flexible and standardized technical platform with low input requirements. The nCounter platform can be used to analyze all types of molecules, including RNA, DNA and proteins. Binding of color coded barcodes to targets of interest allows for either a direct read-out of gene- or protein expression levels or the detection of mutations. Tissue-based biomarker assay development on nCounter led to the FDA approval of the Prosigna™ assay for clinical use in breast cancer subtyping. Previous efforts have also highlighted the potential of this platform to analyze amplified liquid biopsy-derived molecules, although validation studies in the clinical setting are needed. In this thesis we validated the use of the NanoString nCounter platform to analyze material from liquid biopsies and develop clinically relevant biomarker assays.
Universitat Autònoma de Barcelona. Programa de Doctorat en Bioquímica, Biologia Molecular i Biomedicina
APA, Harvard, Vancouver, ISO, and other styles
9

Vasou, Andri. "Development of a novel cell-based screening platform to identify inhibitors of viral interferon antagonists from clinically important viruses." Thesis, University of St Andrews, 2016. http://hdl.handle.net/10023/8266.

Full text
Abstract:
All viruses encode for at least one viral interferon (IFN) antagonist, which is used to subvert the cellular IFN response, a powerful antiviral innate immune response. Numerous in vitro and in vivo studies have demonstrated that IFN antagonism is crucial for virus survival, suggesting that viral IFN antagonists could represent promising therapeutic targets. This study focuses on Respiratory Syncytial Virus (RSV), an important human pathogen for which there is no vaccine or virus-specific antiviral drug. RSV encodes two IFN antagonists NS1 and NS2, which play a critical role in RSV replication and pathogenicity. We developed a high-throughput screening (HTS) assay to target NS2 via our A549.pr(ISRE)GFP-RSV/NS2 cell-line, which contains a GFP gene under the control of an IFN-stimulated response element (ISRE) to monitor IFN- signalling pathway. NS2 inhibits the IFN-signalling pathway and hence GFP expression in the A549.pr(ISRE)GFP-RSV/NS2 cell-line by mediating STAT2 degradation. Using a HTS approach, we screened 16,000 compounds to identify small molecules that inhibit NS2 function and therefore relinquish the NS2 imposed block to IFN-signalling, leading to restoration of GFP expression. A total of twenty-eight hits were identified; elimination of false positives left eight hits, four of which (AV-14, -16, -18, -19) are the most promising. These four hit compounds have EC₅₀ values in the single μM range and three of them (AV-14, -16, -18) represent a chemically related series with an indole structure. We demonstrated that the hit compounds specifically inhibit the STAT2 degradation function of NS2, not the function of NS1 or unrelated viral IFN antagonists. At the current time, compounds do not restrict RSV replication in vitro, hence hit optimization is required to improve their potency. Nonetheless, these compounds could be used as chemical tools to determine the unknown mechanism by which NS2 mediates STAT2 degradation and tackle fundamental questions about RSV biology.
APA, Harvard, Vancouver, ISO, and other styles
10

Ngema, Xolani Terrance. "Metallic nanoparticles with polymeric shell: A multifunctional platform for application to biosensor." University of the Western Cape, 2018. http://hdl.handle.net/11394/6330.

Full text
Abstract:
Philosophiae Doctor - PhD (Chemistry)
Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (MTB) that usually affects the lungs leading to severe coughing, fever and chest pains. It was estimated that over 9.6 million people worldwide developed TB and 1.5 million died from the infectious disease of which 12 % were co-infected with human immunodeficiency virus (HIV) in the year 2015. In 2016 the statistics increased to a total of 1.7 million people reportedly died from TB with an estimated 10.4 million new cases of TB diagnosed worldwide. The development of the efficient point-of-care systems that are ultra-sensitive, cheap and readily available is essential in order to address and control the spread of the tuberculosis (TB) disease and multidrugresistant tuberculosis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Assay platform"

1

Thomas, Ranjeny, and Andrew P. Cope. Pathogenesis of rheumatoid arthritis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0109.

Full text
Abstract:
In depth molecular and cellular analysis of synovial tissue and fluid from patients with rheumatoid arthritis has provided important insights into understanding disease pathogenesis. Advances in the 1980s and 1990s included modern cloning strategies, sensitive and specific assays for inflammatory mediators, production of high-affinity neutralizing monoclonal antibodies, advances in flow cytometry, and gene targeting and transgenic strategies in rodents. In the 21st century, technological platforms offer unparalleled opportunities for systematic and unbiased interrogation of the disease process at a whole-genome level. Here we describe the key molecular and cellular characteristics of the inflamed synovium and how infiltrating cells get there. With this background, we outline current concepts of the different phases of disease, how the first phase of genetic susceptibility evolves into autoimmunity, triggered by the exposome, prior to the onset of clinically apparent inflammatory disease. We then describe the pathways that actively contribute to this early inflammatory phase and document the key effector cells and molecules of the innate and adaptive immune systems that orchestrate and maintain chronic synovial inflammatory responses. We summarize how this inflammatory milieu translates to cartilage destruction and bone resorption in synovial joints, and conclude by reviewing those factors in inflamed synovium that promote immune homeostasis.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Assay platform"

1

Ernst, David, George Bolton, Diether Recktenwald, Mark J. Cameron, Ali Danesh, Desmond Persad, David J. Kelvin, and Amitabh Gaur. "Bead-Based Flow Cytometric Assays: A Multiplex Assay Platform with Applications in Diagnostic Microbiology." In Advanced Techniques in Diagnostic Microbiology, 427–43. Boston, MA: Springer US, 2006. http://dx.doi.org/10.1007/0-387-32892-0_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Daridon, Antoine, William Throndset, Ian Liau, Kevin Farrell, Flora Tseng, Shervin Javadi, and Ian Manger. "A Programmable Cell Assay Platform for Kinetic Studies of a Single Cell." In Micro Total Analysis Systems 2002, 31–33. Dordrecht: Springer Netherlands, 2002. http://dx.doi.org/10.1007/978-94-010-0295-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bardelle, Catherine, and Joanna Boros. "ATM Kinase Inhibitors: HTS Cellular Imaging Assay Using Cellomics™ ArrayScan VTI Platform." In Methods in Molecular Biology, 57–70. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6955-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baldini, F., A. Giannetti, F. Senesi, C. Trono, L. Bolzoni, and G. Porro. "An Optical Platform Based on Fluorescence Anisotropy for C Reactive Protein and Procalcitonine Assay." In Lecture Notes in Electrical Engineering, 127–31. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-3606-3_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McGuinness, Ryan P., Debra L. Gallant, Yen-Wen Chen, Trisha A. Tutana, Donna L. Wilson, John M. Proctor, and H. Roger Tang. "The CellKey® System: A Label-Free Cell-Based Assay Platform for Early Drug Discovery Applications." In Label-Free Technologies for Drug Discovery, 57–70. Chichester, UK: John Wiley & Sons, Ltd, 2011. http://dx.doi.org/10.1002/9780470979129.ch4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Guest, Paul C., Divya Krishnamurthy, and Hassan Rahmoune. "Development of an Assay for Measuring Proprotein-Conversion Activity on a Multiplex Magnetic Bead-Based Array Platform." In Advances in Experimental Medicine and Biology, 321–26. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-52479-5_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bell, David, and Theodoor Visser. "Malaria Diagnostic Platform: Lateral Flow Assays." In Encyclopedia of Malaria, 1–9. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4614-8757-9_105-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sanyal, Suparna, and Marshall Kosovsky. "Materials and assay systems used for three-dimensional cell culture." In Technology Platforms for 3D Cell Culture, 143–72. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781118851647.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cadwell, John J. S., and William G. Whitford. "Three-dimensional cell-based assays in hollow fibre bioreactors." In Technology Platforms for 3D Cell Culture, 327–50. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781118851647.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Maragos, Chris M. "Novel Assays and Sensor Platforms for the Detection of Aflatoxins." In Advances in Experimental Medicine and Biology, 85–93. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0629-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Assay platform"

1

Sweet, Martin R., Mark M. Pickrell, Matthew R. Newell, Richard B. Williams, Robert B. Merl, Colin J. Carrol, and David G. Pelowitz. "The IAEA Universal Nondestructive Assay Data Acquisition Platform (UNAP)." In 2009 1st International Conference on Advancements in Nuclear Instrumentation, Measurement Methods and their Applications (ANIMMA). IEEE, 2009. http://dx.doi.org/10.1109/animma.2009.5503660.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bian, Dakai, Jason C. Tsui, Mikhail Repin, Guy Garty, Helen Turner, Y. Lawrence Yao, and David J. Brenner. "Platform-Dependent Liquid Handling in High-Throughput Biodosimetry Tool." In ASME 2016 11th International Manufacturing Science and Engineering Conference. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/msec2016-8513.

Full text
Abstract:
Due to the need of high speed and efficient biodosimetric assays for triage and therapy in the event of radiological or nuclear attack, a robotically-based automated biodosimetry tool (RABiT) has been developed over the past few years. Adapting the micronucleus assay from filter plates to V-shaped plates presented challenges in the liquid handling, namely cell splashing out of the V-shaped well plate during the cell harvesting, poor cell distribution on the bottom of the image plate during the dispensing, and cell loss from the image plate during the aspiration in the liquid handling process. Experimental and numerical investigations were carried out to better understand the phenomena and mitigate the problems. Surface tension and contact angle among the fluids and the plate wall were accounted for in the discrete and multiphase numerical models. Experimental conditions were optimized based on the numerical results showing the relationship between nozzle speed and amount of splashed liquid, and the relationship between aspiration speed and number of escaped cells. Using these optimized parameters, numbers of micronuclei in binucleated cells showed the same dose dependence in the RABiT-prepared samples as those in the manually prepared ones. Micronucleus assay protocol was fully realized on RABiT.
APA, Harvard, Vancouver, ISO, and other styles
3

Nwankire, Charles E., Robert Burger, Triona O'Connell, Thomas Glennon, and Jens Ducree. "Full integration of a liver assay panel on a centrifugal microfluidic platform." In 2013 Transducers & Eurosensors XXVII: The 17th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS & EUROSENSORS XXVII). IEEE, 2013. http://dx.doi.org/10.1109/transducers.2013.6626781.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hong, Chin-Yih, Herng-Er Horng, Hong-Chang Yang, and Shieh-Yueh Yang. "Bio-Assays Using Bio-Functionalized Magnetic Nanoparticles." In ASME 2008 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. ASMEDC, 2008. http://dx.doi.org/10.1115/detc2008-49503.

Full text
Abstract:
Biocompatible magnetic nano-particles show great potential in bio-magnetic applications. In this work, the feasibility of magnetically labeled immunoassay using bio-compatible magnetic nanoparticles is investigated. To do this, we study the synthesis technologies for magnetic nano-particles Fe3O4, as well as the coating of various bio-probes onto the magnetic nanoparticles to detect bio-targets, such as proteins, virus, etc. Furthermore, the measurement, magnetoreduction assay, for the amount of bio-targets are developed. The results show such merits as high-sensitivity, high-specificity, high-convenience for magnetoreduction assays using magnetic nanoparticles. The whole assay platform is promisingly applied to food inspection, environment monitoring, and even human diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
5

Shin, Dong Jin, Pornpat Athamanolap, Liben Chen, and Tza-Huei Wang. "A mobile phone-operated droplet magnetofluidic assay platform for nucleic acid amplification testing." In 2017 IEEE 12th International Conference on Nano/Micro Engineered and Molecular Systems (NEMS). IEEE, 2017. http://dx.doi.org/10.1109/nems.2017.8017071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Baldini, Francesco, Adolfo Carloni, Ambra Giannetti, Cosimo Trono, Giampiero Porro, and Lorena Tedeschi. "An optical platform based on fluorescence anisotropy for C — reactive protein assay." In 2008 IEEE Sensors. IEEE, 2008. http://dx.doi.org/10.1109/icsens.2008.4716657.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chen, Fan-En, Alexander Y. Trick, Wen Hsieh, Dong Jin Shin, Liben Chen, Emily Chang, Aniruddha Kaushik, and Tza-Huei Wang. "Ratiometric Multiplexed PCR Assay on a Portable Platform for Bacterial Identification from Urine." In 2019 20th International Conference on Solid-State Sensors, Actuators and Microsystems & Eurosensors XXXIII (TRANSDUCERS & EUROSENSORS XXXIII). IEEE, 2019. http://dx.doi.org/10.1109/transducers.2019.8808318.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Costantini, Francesca, Nicola Lovecchio, Augusto Nascetti, Giampiero de Cesare, and Domenico Caputo. "Thin Film Sensor Platform for on-Chip Detection of Fluorescence-Based Aptamer Assay." In 2019 20th International Conference on Solid-State Sensors, Actuators and Microsystems & Eurosensors XXXIII (TRANSDUCERS & EUROSENSORS XXXIII). IEEE, 2019. http://dx.doi.org/10.1109/transducers.2019.8808411.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Booth, Ross, Seungbeom Noh, and Hanseup Kim. "A high-throughput permeability assay platform for shear stress characterization of endothelial cells." In 2014 IEEE 27th International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2014. http://dx.doi.org/10.1109/memsys.2014.6765619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tang, Anson H. L., Antony C. S. Chan, P. Yeung, Barbara P. Chan, Edmund Y. Lam, Kenneth K. Y. Wong, and Kevin K. Tsia. "High-throughput time-stretch imaging cellular assay based on a high-speed spinning platform." In 2016 IEEE Photonics Conference (IPC). IEEE, 2016. http://dx.doi.org/10.1109/ipcon.2016.7831140.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Assay platform"

1

Report on Grouped Peer Review of Scholarly Journals in History, Philosophy and Politics. Academy of Science of South Africa (ASSAf), 2021. http://dx.doi.org/10.17159/assaf.2021/0071.

Full text
Abstract:
The peer review report entitled Report on Grouped Peer Review of Scholarly Journals in History, Philosophy and Politics is the eleventh in a series of discipline-grouped evaluations of South African scholarly journals. This is part of a scholarly assurance process initiated by the Academy of Science of South Africa (ASSAf). The process is centered on multi-perspective, discipline-based evaluation panels appointed by the Academy Council on the recommendation of the Academy’s Committee on Scholarly Publishing in South Africa (CSPiSA). This detailed report presents the peer review panel’s consolidated consensus reports on each journal and provides the panel’s recommendations in respect of DHET accreditation, inclusion on the SciELO SA platform and suggestions for improvement in general. The main purpose of the ASSAf review process for journals is to improve the scholarly publication in the country that is consonant with traditional scholarly practices.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Assay platform' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography